SparVax FDA Approval Status
FDA Approved: No
Brand name: SparVax
Generic name: recombinant Protective Antigen (rPA) anthrax vaccine
Dosage form: Injection
Company: PharmAthene, Inc.
Treatment for: Anthrax Prophylaxis
SparVax is a novel second generation recombinant protective (rPA) anthrax vaccine being developed for administration by intramuscular injection.
Development timeline for SparVax
| Date | Article |
|---|---|
| May 26, 2009 | PharmAthene Submits SparVax Regulatory Strategy to FDA |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
